David Rosmarin MD

Dr. David M. Rosmarin is the Chair of the Department of Dermatology at Indiana University and a clinical investigator. He previously served as Vice-Chair for Research and Education at Tufts Medical Center, focusing on clinical trials for inflammatory disorders of the skin. For his training, Dr. Rosmarin went to medical school at NYU, a dermatology residency at Boston University-Tufts Combined training program, and a fellowship at Brigham and Women's Hospital. Dr. Rosmarin's studies have resulted in him becoming the PI for multicenter trials evaluating topical ruxolitinib in vitiligo, which has led to the first-ever FDA indication for repigmenting vitiligo. Dr. Rosmarin is the first to use dupilumab for bullous pemphigoid, which is now in a phase 3 program for an indication. Clinically, Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult-to-manage inflammatory diseases such as atopic dermatitis. Dr. Rosmarin educates medical students, residents, and research fellows.